View Article3 minute read EEditorialFDA approves supplemental new drug application to expand Mavacamten label for hypertrophic obstructive cardiomyopathybyAlexanderJuly 11, 2023No comments The FDA has approved a supplemental new drug application (sNDA) to expand the label on mavacamten (Camzyos) to…